Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer

Fred R. Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas Cosgriff, Michelle Boyer, Masamichi Ueda, See Phan, David R Gandara

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Micro-Abstract We evaluated the effectiveness of onartuzumab plus first-line platinum-doublet chemotherapy in 109 patients with advanced squamous cell non–small-cell lung cancer. The patients were randomized 1:1 to receive onartuzumab or placebo plus paclitaxel/platinum. Onartuzumab did not confer any clinical benefit in the intent-to-treat population or in the MET immunohistochemistry-positive population. These findings are consistent with the published data for onartuzumab in other lung cancer studies.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalClinical Lung Cancer
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Epithelial Cells
Placebos
Safety
Drug Therapy
Paclitaxel
Population
Lung Neoplasms
Immunohistochemistry
onartuzumab

Keywords

  • Immunohistochemistry
  • MET signaling
  • NSCLC
  • Poor prognosis
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer. / Hirsch, Fred R.; Govindan, Ramaswamy; Zvirbule, Zanete; Braiteh, Fadi; Rittmeyer, Achim; Belda-Iniesta, Cristóbal; Isla, Dolores; Cosgriff, Thomas; Boyer, Michelle; Ueda, Masamichi; Phan, See; Gandara, David R.

In: Clinical Lung Cancer, Vol. 18, No. 1, 01.01.2017, p. 43-49.

Research output: Contribution to journalArticle

Hirsch, Fred R. ; Govindan, Ramaswamy ; Zvirbule, Zanete ; Braiteh, Fadi ; Rittmeyer, Achim ; Belda-Iniesta, Cristóbal ; Isla, Dolores ; Cosgriff, Thomas ; Boyer, Michelle ; Ueda, Masamichi ; Phan, See ; Gandara, David R. / Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 1. pp. 43-49.
@article{88db801fe85345a9a2d18d8b7d6a0188,
title = "Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer",
abstract = "Micro-Abstract We evaluated the effectiveness of onartuzumab plus first-line platinum-doublet chemotherapy in 109 patients with advanced squamous cell non–small-cell lung cancer. The patients were randomized 1:1 to receive onartuzumab or placebo plus paclitaxel/platinum. Onartuzumab did not confer any clinical benefit in the intent-to-treat population or in the MET immunohistochemistry-positive population. These findings are consistent with the published data for onartuzumab in other lung cancer studies.",
keywords = "Immunohistochemistry, MET signaling, NSCLC, Poor prognosis, Squamous cell carcinoma",
author = "Hirsch, {Fred R.} and Ramaswamy Govindan and Zanete Zvirbule and Fadi Braiteh and Achim Rittmeyer and Crist{\'o}bal Belda-Iniesta and Dolores Isla and Thomas Cosgriff and Michelle Boyer and Masamichi Ueda and See Phan and Gandara, {David R}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2016.05.011",
language = "English (US)",
volume = "18",
pages = "43--49",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer

AU - Hirsch, Fred R.

AU - Govindan, Ramaswamy

AU - Zvirbule, Zanete

AU - Braiteh, Fadi

AU - Rittmeyer, Achim

AU - Belda-Iniesta, Cristóbal

AU - Isla, Dolores

AU - Cosgriff, Thomas

AU - Boyer, Michelle

AU - Ueda, Masamichi

AU - Phan, See

AU - Gandara, David R

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Micro-Abstract We evaluated the effectiveness of onartuzumab plus first-line platinum-doublet chemotherapy in 109 patients with advanced squamous cell non–small-cell lung cancer. The patients were randomized 1:1 to receive onartuzumab or placebo plus paclitaxel/platinum. Onartuzumab did not confer any clinical benefit in the intent-to-treat population or in the MET immunohistochemistry-positive population. These findings are consistent with the published data for onartuzumab in other lung cancer studies.

AB - Micro-Abstract We evaluated the effectiveness of onartuzumab plus first-line platinum-doublet chemotherapy in 109 patients with advanced squamous cell non–small-cell lung cancer. The patients were randomized 1:1 to receive onartuzumab or placebo plus paclitaxel/platinum. Onartuzumab did not confer any clinical benefit in the intent-to-treat population or in the MET immunohistochemistry-positive population. These findings are consistent with the published data for onartuzumab in other lung cancer studies.

KW - Immunohistochemistry

KW - MET signaling

KW - NSCLC

KW - Poor prognosis

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85008419652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008419652&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.05.011

DO - 10.1016/j.cllc.2016.05.011

M3 - Article

C2 - 27461773

AN - SCOPUS:85008419652

VL - 18

SP - 43

EP - 49

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -